Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
In the extended Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozolmide, which is easy to use clinically and generally well tolerated.
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median…
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity.
A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer
‘Casodex’ 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable and has an acceptable tolerability profile.
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
- V. Bramwell, H. Mouridsen, +7 authors R. Sylvester
- MedicineEuropean journal of cancer & clinical oncology
- 1 March 1987
A higher response rate with less myelosuppression suggests that IFOS may have advantages over CYCLO in combination therapy, and serious infections occurred in approx.
The effect of combination chemotherapy on ovarian function in women treated for hodgkin's disease
- E. Whitehead, S. Shalet, G. Blackledge, I. Todd, D. Crowther, C. Beardwell
- 15 September 1983
Estrogen replacement therapy was of definite benefit in the symptomatic patients with premature ovarian failure; however, subsequently 4 developed amenorrhea and 3 oligomenorrhea, suggesting that these patients had not been protected from chemotherapy‐induced ovarian damage.
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.
An analysis of five phase II studies of treatment in ovarian cancer to determine whether factors other than the efficacy of the drug affect response found interval and the FIGO stage of the patient to be of importance.
Growth factors and their receptors: new targets for prostate cancer therapy.
Low-molecular-weight inhibitors of the EGFR tyrosine kinase also in clinical development include OSI-774, PD182905, PKI-166, CI-1033, and ZD1839, which has shown encouraging results in patients with prostate cancer in phase 1 trials.
Maintenance chlorambucil after CVP in the management of advanced stage, low‐grade histologic type non‐Hodgkin's lymphoma: A randomized prospective study with an assessment of prognostic factors
One hundred sixty‐two patients with Stages III and IV non‐Hodgkin's lymphoma of low‐grade histologic type were treated with combination chemotherapy using cyclophosphamide, vincristine, and…
Intervention debulking surgery in advanced epithelial ovarian cancer
- C. Redman, J. Warwick, D. Luesley, R. Varma, F. Lawton, G. Blackledge
- MedicineBritish journal of obstetrics and gynaecology
- 1 February 1994
Whether intervention debulking surgery improves survival in patients with advanced ovarian cancer who have bulky (> 2 cm) residual disease after primary surgery is studied.
Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
It is suggested that stilboestrol should no longer be used for prostate cancer when equally effective alternative treatments are available.